Concortis Biotherapeutics was established to focus on developing next generation antibody-drug conjugates (ADCs) to address unmet medical needs. Currently, we have approximately 20 ADC programs in preclinical development, and in 2017, we plan to enroll patients in four clinical trials. Our mission is to be the leading developer of next generation “first-in-class” and “best-in-class" ADCs.
Antibody Drug Conjugate Technology
Antibody-drug conjugates (ADCs) are a new type of targeted cancer therapy. They covalently connect potent cytotoxic drugs (referred to as toxins) to antibodies or antibody fragments via chemical linkers, providing a means to increase the chemotherapeutic targeting of the drug to cancer cells. ADCs also have reduced side effects, compared to traditional treatments, because targeting cancer cells specifically leads to fewer drugs affecting healthy cells.
Concortis has developed a core ADC technology platform that sets a new industry standard for ADCs and will transform biologics such as antibodies, proteins, and peptides into therapeutics that are more efficient. Using our ADC technology, G-MAB™ antibody library, proprietary toxins, and K-Lock™ and C-Lock™ conjugation methods, we create a comprehensive technology platform that supports our scientific research, focusing on ADCs for targeted cancer therapy.
G-MAB Antibody Library
Our parent company, Sorrento Therapeutics, has developed G-MAB™ technology, one of the largest, most complete, and fully diverse human antibody libraries in the industry. This antibody library was designed to facilitate the rapid identification and selection of highly specific, monoclonal candidates.
We have developed a panel of proprietary toxins, derived from natural cytotoxic compounds, with our in-house chemical design and synthesis to optimize performance of our payloads. Various structural modifications of known compounds were implemented to address issues such as efficacy, toxicity, conjugation, and stability.
The therapeutic potential of many ADCs that are currently in preclinical or clinical development, including FDA-approved ado-trastuzumabemtansine (Kadcyla®), suffers from very narrow therapeutic windows. There is a constant need in the ADC field for further improvement.
The FDA-approved ADC, brentuximabvedotin (Adcetris®), is produced through reduction of four inter-chain disulfide bonds followed by partial maleimide conjugation to the exposed sulfhydryl groups. ADCs generated with this approach are polydisperse and the drug-to-antibody ratios (DAR) may range from 0–8.
As the industry leader in developing next generation antibody-drug conjugates (ADCs), our technology sets a new standard. Our robust pipeline of antibody-based therapies is designed to address significant, unmet medical needs in the community.
Concortis Biotherapeutics presented at the AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16-20, 2016. Data presented included in vitro studies of an anti-5T4 antibody drug conjugate (ADC) and preclinical studies of an anti-c-Met ADC in non-small cell lung cancer (NSCLC) models
October 10-13, 2016 | San Diego, CA
Concortis Biotherapeutics is proud to be one of the senior partners at the 7th Annual World ADC Summit. For more info, please visit here.
- Mission Statement from CEO
- Board of Directors
- Scientific Advisors
- Internal Pipeline
- Partnered Pipeline
- Conference Posters
- Press Release
- Scientific Inquiries
- Partnership Inquiries
- Human Resources
- Corporate Address